Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.
Latest from Alaric DeArment
The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.